{"id":"W4282028151","doi":"10.1200/jco.2022.40.16_suppl.589","title":"Neoadjuvant giredestrant (GDC-9545) plus palbociclib (P) versus anastrozole (A) plus P in postmenopausal women with estrogen receptor–positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Final analysis of the randomized, open-label, international phase 2 coopERA BC study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Clinical endpoint; Anastrozole; Palbociclib; Internal medicine; Urology; Estrogen receptor; Breast cancer; Gastroenterology; Confidence interval; Phases of clinical research; Neoadjuvant therapy; Oncology; Gynecology; Cancer; Randomized controlled trial; Tamoxifen; Chemotherapy; Metastatic breast cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003430273,0.0003926137,0.003870453,0.0004380152,0.0001723753,0.00003742888,0.001012891,0.0001649796,0.00168833],"category_scores_gemma":[0.0007338237,0.0002496538,0.0003649738,0.001488851,0.0008055127,0.0003282937,0.000398332,0.001665377,0.000002073416],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002627628,"about_ca_system_score_gemma":0.004421352,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003511455,"about_ca_topic_score_gemma":0.001270631,"domain_scores_codex":[0.992408,0.00240377,0.002978347,0.0005210505,0.001166457,0.0005223998],"domain_scores_gemma":[0.9921734,0.002901913,0.003174553,0.0003930147,0.000974088,0.0003829793],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8763077,0.009276284,0.04321403,0.000008457953,0.01667407,0.0008238595,0.002468525,0.01187069,0.0003047645,0.00004825598,0.00007260808,0.03893076],"study_design_scores_gemma":[0.7344059,0.04039778,0.2121087,0.0001435239,0.004172539,0.0003043215,0.004439049,0.002131274,0.00005466497,0.00003270142,0.001516427,0.0002930966],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9894516,0.0002108332,0.00008451539,0.007099514,0.0009800856,0.001519762,0.000435786,0.00001190341,0.0002059784],"genre_scores_gemma":[0.9969693,0.0001663783,0.001157464,0.000840584,0.00029926,0.0002370499,0.00002912665,0.0000463905,0.0002544041],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1688946,"threshold_uncertainty_score":0.9999956,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0776512974025615,"score_gpt":0.4460083337624238,"score_spread":0.3683570363598623,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}